Articles

Poll

Podcasts

Slideshows

Videos

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

In a new study, patients with ADHD on cannabis-based medicinal products had significant improvements for anxiety, sleep quality, and health-related quality of life.

Cannabis Treatment Linked to Improving Quality of Life in ADHD Patients

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

Long-Term ADHD Medication Use Linked to Potential Risk of Cardiovascular Diseases

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Unlicensed Stimulant Doses in Adult ADHD Barely Reduce Symptoms Compared to Licensed Doses

Two pivotal phrase 3 centanafadine trials show positive outcomes for children and adolescents with ADHD.


Centanafadine Shows Promise in Phase 3 Trials for Adolescent ADHD 

The rates of pediatric and adolescent treatment for depression, anxiety, ADHD, and behavior disorders vary by age, income level, and region.

Mental Disorders Treatment Rates Remain Low Among Children and Adolescents

Adult ADHD is associated with a 2.77-fold increased risk of dementia, according to new research.


New Study Finds Link Between Adult ADHD and Dementia Risk

Solriamfetol could potentially serve as a new ADHD treatment if future research goes positively.

Craig Surman, MD: Sleep Drug Solriamfetol Can Effectively Treat ADHD

Solriamfetol, typically used to treat narcolepsy and sleep apnea, has demonstrated it can reduce ADHD symptoms with no adverse cardiovascular effects.

Sleep Medication Solriamfetol Effectively Treats ADHD, Study Finds

These approvals of generics by the FDA can help to provide for patients with ADHD or BED the same clinical benefits as well as risks as the drugs’ brand-name counterparts. 

FDA Announces Approval of Generics for ADHD in Younger Patients, Binge-Eating Disorder in Adults

The analysis of 500+ patients with ADHD shows no statistically significant evidence linking stimulant treatment to later substance use, indicating that stimulant medication did not increase or decrease the risk of substance use in adolescence or adulthood.

No Evidence of Substance Abuse in Patients Taking Stimulant Medication for ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.